A recent study published in the Journal of Neuroimmune Pharmacology, and by the National Institute of Health, has found that delta-9-tetrahydrocannabinol (THC) – one of the prime compounds in cannabis – can potentially stop organ transplant rejections from taking place.
The study, which found that the higher the dose of THC, the higher the chance of protecting against rejection, also found synthetic cannabinoids to share a similar protective ability.
“This data supports the potential of this class of compounds [cannabinoids] to be used as therapies to prolong graft survival in transplant patients”, the study concludes.
According to researchers – although this study is one of the most detailed of its type – these findings aren’t particularly new; Cannabinoids were reported to have effects on immune responses as early as the 1970s, states the study.
The study was conducted by researchers at Temple University in Philadelphia.